The CAR T-cell therapy market is projected to reach USD 29.0 billion by 2029 from an estimated USD 5.5 billion in 2024, at a CAGR of 39.6% during the forecast period. The rising global prevalence of cancer, particularly hematologic malignancies and certain solid tumors, is a primary driver for the CAR T-cell therapy market. Additionally, ongoing advancements in CAR T-cell technology, including improvements in CAR design, vector delivery systems, and manufacturing processes enhance therapy efficacy, safety, and scalability. This will lead to broader adoption and application of CAR T-cell therapies across various cancer types, driving market growth.
Based on product, the CAR T-cell therapy market is broadly segmented into Abecma (idecabtagene vicleucel), Breyanzi (lisocabtagene maraleucel), Carvykti (ciltacabtagene autoleucel), Yescarta (axicabtagene ciloleucel), Tecartus (brexucabtagene autoleucel), Kymriah (tisagenlecleucel) and other products. Yescarta dominates the market, accounting for the largest share during the forecast period. Yescarta’s early entry into the market in 2017 allowed Gilead Sciences, Inc. to establish a strong brand presence and gain significant experience in commercialization and market dynamics. Yescarta’s robust clinical efficacy, with high response rates and durable remissions in patients with relapsed or refractory large B-cell lymphoma further drives market growth.
Based on the target, the CAR T-cell therapy market is segmented into CD19, BCMA and other target antigens. In 2023, the CD19 segment accounted for the largest share of the CAR T-cell therapy market. the initial success of CD19 CAR T-cell therapies in treating Acute Lymphoblastic Leukemia (ALL) and large B-cell Lymphoma prompted further research and development to expand indications. For instance, Breyanzi by Bristol-Myers Squibb Company was initially approved by the FDA in 2021 for Large B-cell Lymphoma and in 2024 for Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma, and Follicular Lymphoma. Ongoing clinical trials are also exploring the efficacy of CD19 CAR T-cell therapies in other hematologic malignancies and combination therapies. This broadening of indications is expected to increase the patient pool for CAR T-cell therapy, thus driving market growth
Based on indication, the CAR T-cell therapy market is segmented into Multiple Myeloma, B-Cell Lymphoma (BCL), Acute Lymphoblastic Leukemia (ALL) and other indications. In 2023, B-Cell Lymphoma (BCL) accounted for the largest share of the CAR T-cell therapy market due to its rising prevalence globally. For instance, roughly 20% of lymphoma cases in the United States are classified as Follicular Lymphoma and about 5% of lymphomas are Mantle Cell Lymphomas. This widespread prevalence of B-cell Lymphomas provides a patient pool for the growth of CAR T-cell therapies thus driving market growth.
Based on demographic, the CAR T-cell therapy market is segmented into adult and pediatric. In 2023, the adult demographic segment accounted the largest share of 96.4% of the CAR T-cell therapy market. As the global population ages, the incidence of these cancers is expected to rise, expanding the potential market for CAR T-cell therapies. For instance, as per the American Cancer Society, the estimates for Multiple Myeloma in the United States for 2024 were 35,780 new cases diagnosed (19,520 in men and 16,260 in women) and about 12,540 deaths expected to occur (7,020 in men and 5,520 in women). The rising prevalence of these cancers is expected to drive market growth.
Based on end user, the CAR T-cell therapy market is segmented into hospitals, long term care facilities and specialty centers. In 2023, Hospitals accounted for the largest share of the CAR T-cell therapy market. The dominant share of this segment can primarily be attributed to collaborations between pharmaceutical companies and hospitals effectively facilitating the delivery of CAR T-cell therapies to patients. Companies consistently collaborate with hospitals to streamline processes, ensuring timely and efficient treatment. For instance, in 2024, Apollo Hospitals Enterprises Ltd. (India) collaborated with ImmunoACT (India) to develop NexCar 19, an autologous CAR T-cell therapy, across 16 Apollo Hospitals in India for patients aged 15 and older with B-cell lymphomas and B-acute lymphoblastic leukemia.
The key regional markets for the global CAR T-cell therapy market are North America, Europe, Asia Pacific, Latin America and the Middle East & Africa. In 2023, North America commanded the largest share in the CAR T-cell therapy market in 2023 and is expected to grow at a significant CAGR of during the forecast period. Increasing research activities for developing CAR T-cell therapies and growing awareness of personalized medicine have resulted in the approval of six autologous CAR T-cell therapies in the US, with multiple therapeutic products in clinical pipelines for several indications. In recent years, North America has witnessed significant growth in advancements in medical research, increasing clinical trials, and the expanding biopharmaceutical industry. For instance, Bristol-Myers Squibb Company (US) invested approximately USD 14 billion until 2023 to develop CAR T-cell therapies for the oncology indication.
